Anti-CD38 antibodies are a crucial component of these novel agents, demonstrating remarkable efficacy, particularly when combined with other standard anti-myeloma regimens, thus providing a valuable addition to the therapeutic arsenal for MM [3,4]. The gene discussed is CD38; the disease is plasma cell myeloma.